Alnylam Pharmaceuticals, Inc.
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE
Last updated:
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA
Status:
Application
Type:
Utility
Filling date:
14 Sep 2021
Issue date:
4 Aug 2022